While andexxa appears to have good hemostatic efficacy, it has greater risk of thrombotic events, specifically cerebrovascular events, compared to kcentra, and no differences in mortality. Unlike kcentra, does not include any endogenous anticoagulants This gives factor ix complex a greater tendency to promote thrombosis However, it is probably riskier and is supported by less evidence, when compared to kcentra. Patients with acute intracerebral hemorrhage who are receiving factor xa inhibitors have a risk of hematoma expansion The effect of andexanet alfa, an agent that reverses the effects of factor xa.
It was approved by the fda in may 2018 and became commercially available in the first quarter of 2019. With a paucity of literature comparing the 2 agents, there is clinical. This study aims to compare the efficacy and outcomes of andexanet alfa and kcentra for reversal of apixaban or rivaroxaban in bleeding or surgical patients Introduction doac reversal is warranted for patients presenting with intracranial hemorrhage (ich) While data suggests that andexxa is superior to kcentra in reversal of factor xa inhibitors in ich, there is no direct evidence that it is superior in preventing hemorrhagic.
OPEN
